These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 30553760)

  • 41. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
    Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
    J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A deep learning model for generating [
    Sanaat A; Boccalini C; Mathoux G; Perani D; Frisoni GB; Haller S; Montandon ML; Rodriguez C; Giannakopoulos P; Garibotto V; Zaidi H
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3518-3531. PubMed ID: 38861183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
    Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
    BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study.
    Ou YN; Xu W; Li JQ; Guo Y; Cui M; Chen KL; Huang YY; Dong Q; Tan L; Yu JT;
    Alzheimers Res Ther; 2019 Jun; 11(1):57. PubMed ID: 31253185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
    Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
    Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer's dementia: a meta-analysis.
    Ma HR; Sheng LQ; Pan PL; Wang GD; Luo R; Shi HC; Dai ZY; Zhong JG
    Transl Neurodegener; 2018; 7():9. PubMed ID: 29713467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.
    Smailagic N; Lafortune L; Kelly S; Hyde C; Brayne C
    J Alzheimers Dis; 2018; 64(4):1175-1194. PubMed ID: 30010119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
    Chiba Y; Fujishiro H; Iseki E; Kasanuki K; Sato K
    J Neuroimaging; 2019 Nov; 29(6):712-720. PubMed ID: 31199036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration.
    Levin F; Ferreira D; Lange C; Dyrba M; Westman E; Buchert R; Teipel SJ; Grothe MJ;
    Alzheimers Res Ther; 2021 Feb; 13(1):49. PubMed ID: 33608059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?
    Verfaillie SC; Adriaanse SM; Binnewijzend MA; Benedictus MR; Ossenkoppele R; Wattjes MP; Pijnenburg YA; van der Flier WM; Lammertsma AA; Kuijer JP; Boellaard R; Scheltens P; van Berckel BN; Barkhof F
    Eur Radiol; 2015 Oct; 25(10):3050-9. PubMed ID: 25899416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Alzheimers Dis; 2016 Sep; 54(2):559-68. PubMed ID: 27567846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
    Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A modified method of 3D-SSP analysis for amyloid PET imaging using [¹¹C]BF-227.
    Kaneta T; Okamura N; Minoshima S; Furukawa K; Tashiro M; Furumoto S; Iwata R; Fukuda H; Takahashi S; Yanai K; Kudo Y; Arai H
    Ann Nucl Med; 2011 Dec; 25(10):732-9. PubMed ID: 21792587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain fluorodeoxyglucose (FDG) PET in dementia.
    Kato T; Inui Y; Nakamura A; Ito K
    Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.